Analysis of Risk in MDS Over Time - Comparison of Treated vs Untreated Patients
NCT04676945 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 9179
Last updated 2022-11-22
Summary
A comparison of treated vs untreated patients with MDS with a sample size of approximately 8000 patients in 11 countries.
Conditions
Sponsors & Collaborators
-
Celgene Corporation
collaborator INDUSTRY -
Michael Pfeilstöcker
lead OTHER
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-08-21
- Primary Completion
- 2021-08-20
- Completion
- 2022-11-21
Countries
- Austria
Study Locations
More Related Trials
-
Detection of Residual Disease in Children Receiving Therapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT00003790 ·Status: COMPLETED
-
Registry of Myelodysplastic Syndromes and Therapy-related Acute Myeloid Leukemia
NCT06956755 ·Status: RECRUITING
-
Lifestyle-modifying Interventions in Low-risk MDS Patients
NCT05433805 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression (P05052)
NCT00687323 ·Status: COMPLETED ·Phase: PHASE2
-
Personalized Medicine Program on Myelodysplastic Syndromes: Characterization of the Patient's Genome for Clinical Decision Making and Systematic Collection of Real World Data to Improve Quality of Health Care
NCT04212390 ·Status: COMPLETED
-
Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome
NCT02117219 ·Status: COMPLETED ·Phase: PHASE1
-
A Prospective, Multicentre European Registry for Newly Diagnosed Patients With Myelodysplastic Syndromes
NCT00600860 ·Status: UNKNOWN
-
Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS
NCT03502668 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Prospective Study of Molecular Predictors of Survival in Myelodysplastic Syndromes
NCT02619565 ·Status: COMPLETED ·Phase: NA
-
A Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic Syndrome
NCT06304103 ·Status: RECRUITING ·Phase: PHASE2
-
Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS
NCT04810611 ·Status: TERMINATED ·Phase: PHASE1
-
Individual Molecular MRD Monitoring for MDS Patients After Allo-SCT
NCT02872662 ·Status: COMPLETED
-
Phase II Cont. IV of ON 01910.Na in MDS w/ Trisomy 8/Intermed-1, 2/High Risk
NCT00987584 ·Status: COMPLETED
-
A Study to Evaluate the MNV-201 in Patients With Low Risk MDS
NCT06465160 ·Status: RECRUITING ·Phase: PHASE1
-
Mean Platelet Volume and Its Relation to Risk Stratification of Myelodysplastic Syndromes
NCT05204953 ·Status: COMPLETED
-
AML-MDS Novel Prognostic Tests Clinical Study
NCT01685619 ·Status: COMPLETED
-
Repurposed Drugs to Improve Haematological Responses in Myelodysplastic Syndromes
NCT04997811 ·Status: RECRUITING ·Phase: PHASE2
-
An European Platform for Translational Research in Myelodysplastic Syndromes
NCT04174547 ·Status: UNKNOWN
-
Molecular Mechanisms of Disease Relapse After Allogenic Stem Cell Transplantation in MDS Patients
NCT04587856 ·Status: RECRUITING ·Phase: NA
-
Allogeneic HSCT in MDS Patients Based on Risk According to R-IPSS
NCT04801563 ·Status: UNKNOWN ·Phase: NA
-
Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome
NCT00043134 ·Status: UNKNOWN ·Phase: PHASE3
-
MBG453 in Lower Risk MDS
NCT04823624 ·Status: TERMINATED ·Phase: PHASE2
-
Immunophenotyping of Blood Cells in the Diagnosis Work-up of Myelodysplastic Syndromes
NCT03621241 ·Status: RECRUITING
-
Phase 1 Trial of ASTX727 in Subjects With Lower-risk Myelodysplastic Syndromes
NCT03906695 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Topotecan in Treating Patients With Myelodysplastic Syndrome
NCT00003675 ·Status: COMPLETED ·Phase: PHASE2